Key Takeaways:
- Cauldron Ferm has closed a $13.25 million Series A2 round led by Main Sequence Ventures, bringing total funding to $26 million
- The round includes participation from Horizons Ventures, SOSV, and NGS Super
- Cauldron Ferm has been named to Fast Company’s 2026 list of the World’s Most Innovative Companies
- The company is the first to demonstrate continuous fermentation for synthetic biology strains at 10,000-liter industrial scale
- New capital will support retrofitting existing facilities and expanding demo-scale operations in Australia and the U.S.
Cauldron Ferm Closes $13.25M Series A2 Round
Cauldron Ferm, an advanced biomanufacturing company, has announced the closing of a $13.25 million Series A2 priced funding round, bringing its total capital raised to $26 million. The round was led by Main Sequence Ventures, with participation from Horizons Ventures, SOSV, and NGS Super, one of Australia’s largest pension funds.
Alongside the funding announcement, Cauldron Ferm has been named to Fast Company’s 2026 list of the World’s Most Innovative Companies.
What Is Hyper-Fermentation?
At the core of Cauldron Ferm’s offering is its proprietary continuous “hyper-fermentation” platform. Biomanufacturing relies on living cells — specifically bio-engineered microbes — that convert simple inputs such as sugars into valuable products. Cauldron’s technology keeps these microbes in a sustained, highly productive steady state, allowing processes to run continuously over extended periods.
The approach is designed to increase output while lowering production costs, with the goal of making bio-based products cost-competitive with conventional industrial alternatives.
Cauldron Ferm is the first company to demonstrate true industrial-scale continuous fermentation for synthetic biology strains at 10,000-liter scale.
Commercial Applications
The company has demonstrated hyper-fermentation across client projects involving bio-based food ingredients, chemicals, and nutraceuticals.
Cauldron Ferm & Investors Leadership Commentary
“For biomanufacturing to compete in industrial sectors, bioproducts have to deliver on costs, scale, and quality. Bioprocess innovation is how we get there,” said Michele Stansfield, Co-founder and CEO of Cauldron Ferm. “We’re honoured to be backed by a dedicated group of experienced investors and proud to be recognised as one of the World’s Most Innovative Companies.”
Ben Squires, Chief Investment Officer at NGS Super, explained the rationale behind the investment: “Cauldron’s continuous ‘hyper-fermentation’ platform is focused on the key constraint in the sector: improving productivity and unit economics at industrial scale. That combination of technology differentiation and real-world commercial validation is why we decided to invest.”
Phil Morle, Partner at Main Sequence Ventures, added: “Cauldron is proving that biology can run continuously, predictably, and at the volumes global supply chains demand. Hyper-fermentation closes the gap between breakthrough strains and reliable, cost-competitive production.”
How Cauldron Ferm Plans to Deploy the Funds
Facility Expansion and Government Support
The new capital will be directed toward meeting demand from governments and corporations investing in biomanufacturing infrastructure. Cauldron Ferm is currently working with corporate partners to evaluate retrofitting existing facilities to deploy hyper-fermentation technology at partner sites.
The company has also secured non-dilutive government grants in both Australia and the United States to support expansion of its demo-scale operations in Orange, New South Wales, and to advance planning for industrial-scale production.
